Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NeuMoDx Molecular

Explore full profile

Solutions for molecular diagnostic (mdx) testing

Ann Arbor, United StatesFounded 2012Biotech & Life Sciences
Valuation $100–250M Last recorded · 2018
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for NeuMoDx Molecular and the history behind them.

About NeuMoDx Molecular

Neumodx is a cutting-edge startup specializing in automated molecular diagnostic systems. Their primary focus is on creating scalable platforms that streamline the entire molecular diagnostic process, from sample collection to final results. These systems are designed to serve modern clinical laboratories, offering solutions that are both efficient and flexible.

Neumodx's product lineup includes various test strips and assays, such as the HPV Test Strip and the SARS-CoV-2 Assay. These products are crucial for detecting specific pathogens and diseases, making them highly relevant in today's healthcare landscape. The company also offers proprietary reagents and consumables that are stable at room temperature, reducing waste and enhancing operational efficiency.

One of the standout features of Neumodx's systems is their "continuous random access" capability. This means that samples and testing consumables can be loaded at any time, allowing for up to 8 hours of unattended operation. This feature is particularly beneficial for clinical labs that require high throughput and minimal downtime. The systems are also scalable, meaning they can be adjusted to meet the varying needs of different laboratories, whether they require the 96 or 288 Molecular System.

Neumodx operates in the molecular diagnostics market, which is a rapidly growing sector within the broader healthcare industry. Their business model revolves around selling their diagnostic platforms and the associated consumables. By providing a comprehensive solution that integrates sample handling, liquid transport, and diagnostic testing, Neumodx ensures a steady revenue stream from both the initial sale of their systems and the ongoing sale of consumables.

In summary, Neumodx is revolutionizing the molecular diagnostics field with their fully automated, scalable platforms that offer continuous random access and high operational efficiency. Their products are designed to meet the needs of modern clinical laboratories, making molecular diagnostics simpler and more effective.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2012
Headquarters
Ann Arbor, United States
Employees
20
Open positions
None listed
Dealroom signal
26.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Testing, Biotechnology, Biotech and Pharma, Hard Tech, medical testing, DT and LS, science-based
Client focus
b2b

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Sep 2020 $248M — Qiagen —
LATE VCOther financing May 2018 $20M $80M Undisclosed —
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

NeuMoDx Molecular website traffic

Latest recorded traffic for NeuMoDx Molecular is 1.2K monthly website visits, up 71.4% over the last three months.

Latest monthly visits1.2K 3-month web change+71.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Wolverine Venture Fund
  • Venture Investors Health Fund
  • Robert W. Baird & Co.
  • Baird Capital
  • Arboretum Ventures

Series B and later1 investor entered at this stage

  • Pfizer Ventures

Other known investors1 additional known investor

  • Qiagen
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NeuMoDx Molecular on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NeuMoDx Molecular’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.